Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7105166 Soluble CTLA4 mutant molecules and uses thereof

Patent 7105166 was granted and assigned to Bristol-Myers Squibb on September, 2006 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Bristol-Myers Squibb

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

71051660

Patent Inventor Names

Robert J. Peach0

William Brady0

Jeffrey A. Ledbetter0

Jurgen Bajorath0

Nitin Damle0

Peter S. Linsley0

Philip Wallace0

Date of Patent

September 12, 2006

Patent Application Number

096099150

Date Filed

July 3, 2000

Patent Citations Received

‌

US Patent 11753458 CTLA-4 variant immunomodulatory proteins and uses thereof

Patent Primary Examiner

‌

Lorraine Spector

Patent abstract

The present invention provides soluble CTLA4 mutant molecules which bind CD80 and/or CD86 antigen.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7105166 Soluble CTLA4 mutant molecules and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API